Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998

Journal of Infectious Diseases

Volumn 182, Issue 4, 2000, Pages 1169-1176

  Sacchi, Claudio T ^a,c   Whitney, Anne M ^a   Popovic, Tanja ^a   Beall, David S ^a   Reeves, Michael W ^a   Plikaytis, Brian D ^a   Rosenstein, Nancy E ^a   Perkins, Brad A ^a   Tondella, Maria L C ^b   Mayer, Leonard W ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIUM ISOLATE; NEISSERIA MENINGITIDIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; VACCINE PRODUCTION;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HUMAN; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE; PORINS; UNITED STATES; VARIATION (GENETICS);

EID: 0033795822     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315833     Document Type: Article

References (49)

1. The changing epidemiology of meningococcal disease in the United States, 1992-1996
2. Bacterial meningitis in the United States in 1995
3. Serogroup C meningococcal outbreaks in the United States: An emerging threat
4. Neisseria meningitidis outbreaks in the United States, 1994-97
5. Meningococcal vaccines: Past, present and future
6. Neisseria meningitidis: Vaccines and vaccine candidates
7. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
8. Efficacy, safety, and immunogenicity of a meningococcal group B (15:Pl.3) outer membrane protein vaccine in Iquique, Chile: Chilean National Committee for Meningococcal Disease
9. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
10. Vaccines against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
11. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine
12. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial
13. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
14. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
15. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among adults in Iceland
16. Human antibody response to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
17. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine
18. Five structural classes of major outer membrane proteins in Neisseria menigitidis
19. Unified nomenclature for pathogenic Neisseria species
20. Definition of meningococcal class I OMP subtyping antigens by monoclonal antibodies
21. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA
22. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes
23. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with Norwegian group B meningococcal vaccine
24. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB
25. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine
26. Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines
27. Specificity of human bactericidal antibodies against PorA P1,7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine
28. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein
29. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
30. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
31. Immunogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
32. Topology of outer membrane porins in pathogenic Neisseria spp
33. Class I outer membrane protein of Neisseria meningitidis: Epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology
34. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature
35. Comparison of the class l outer membrane proteins of eight serological reference strains of Neisseria meningitidis
36. Structural and evolutionary inference from molecular variation in Neisseria porins
37. Distribution of Neisseria meningitidis serogroup B serotypes and serosubtypes circulating in the United States: Identification of predominant antigens for inclusion in multivalent outer membrane protein-based vaccines
38. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design
39. Epidemic serogroup B meningococcal disease in Oregon: The evolving epidemiology of the ET-5 strain
40. A comprehensive set of sequence analysis programs for the VAX
41. SplitsTree: Analyzing and visualizing evolutionary data
42. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:Pl.4
43. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex
44. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway
45. Use of transformation to construct antigenic hybrids of the class l outer membrane protein in Neisseria meningitidis
46. Meningococcal disease in The Netherlands, 1958-1990: A steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis
47. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine
48. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine
49. Meningococcal vaccines: Present and future